GDF15 and obesity due to melanocortin 4 receptor deficiency: In the future, based on its extensive pathophysiological mechanism, GDF-15 also carries potential for therapeutic applications, and studies are currently ongoing on its effectiveness against cardiometabolic disease, non-alcoholic fatty liver disease, and obesity (Wang et al., 2021).